EGA announces repositioning and new name

14 March 2016

The European Generic and Biosimilar Medicines Association has changed its name to Medicines for Europe.

The group represents the pharmaceutical companies supplying the largest share of medicines across Europe and describes itself as the voice of the generic, biosimilar and value added medicines industries.

Medicines for Europe president Jacek Glinka said; “Medicines for Europe Better access. Better health reflects our industries’ purpose and strategic objectives. As an organization we have been through an incredible journey responding to the changes that have taken place in the pharmaceutical industry and European healthcare environment. I invite stakeholders and policy-makers to engage with us to deliver access to high quality medicines for all European patients.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK